Humana (NYSE:HUM) Coverage Initiated by Analysts at Guggenheim

Equities researchers at Guggenheim began coverage on shares of Humana (NYSE:HUM - Get Free Report) in a research note issued on Wednesday, Marketbeat.com reports. The firm set a "buy" rating and a $326.00 price target on the insurance provider's stock. Guggenheim's target price would suggest a potential upside of 15.43% from the company's previous close.

A number of other equities research analysts have also recently issued reports on HUM. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $290.00 target price on shares of Humana in a research report on Wednesday, February 12th. Mizuho upped their price target on shares of Humana from $305.00 to $316.00 and gave the company an "outperform" rating in a report on Wednesday, April 9th. Piper Sandler upped their price target on Humana from $270.00 to $288.00 and gave the stock a "neutral" rating in a report on Wednesday, January 15th. Truist Financial boosted their price target on Humana from $260.00 to $290.00 and gave the company a "hold" rating in a research note on Monday, January 6th. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $283.00 price target on shares of Humana in a research report on Wednesday, February 12th. Seventeen investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $288.60.

Remove Ads

Humana Stock Down 4.3 %

Shares of NYSE:HUM traded down $12.61 during midday trading on Wednesday, hitting $282.43. 680,327 shares of the stock were exchanged, compared to its average volume of 1,748,128. The company has a market capitalization of $34.09 billion, a PE ratio of 28.38, a P/E/G ratio of 2.05 and a beta of 0.62. The business's fifty day simple moving average is $265.55 and its two-hundred day simple moving average is $270.35. Humana has a 52-week low of $213.31 and a 52-week high of $406.46. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76.

Humana (NYSE:HUM - Get Free Report) last announced its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. As a group, research analysts predict that Humana will post 16.47 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Humana

A number of large investors have recently bought and sold shares of the company. FPC Investment Advisory Inc. bought a new position in shares of Humana during the fourth quarter valued at $27,000. Centricity Wealth Management LLC acquired a new position in shares of Humana during the fourth quarter valued at about $30,000. LFA Lugano Financial Advisors SA lifted its holdings in shares of Humana by 56.3% in the fourth quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider's stock valued at $32,000 after purchasing an additional 45 shares in the last quarter. OFI Invest Asset Management purchased a new stake in shares of Humana in the fourth quarter valued at about $33,000. Finally, Riverview Trust Co bought a new position in shares of Humana in the first quarter valued at approximately $34,000. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.